sampleamylin / CagriSema
98%+ · 5mg · Lyophilized · MW: 3260
Bulk discount
3+ pcs
€42.75
−5%
5+ pcs
€40.50
−10%
10+ pcs
€38.25
−15%
Discount is applied automatically at checkout.
Enter your email and we'll notify you when it's back:
Free shipping over €49
This product is sold strictly for in lab conditions (in vitro) research purposes. Not approved for human consumption.
Verified above 98%
98%+ verified — most batches reach 99%+
Included
Independent analysis from accredited laboratories
EU Shipping
3-7 days across the EU (Bulgaria — 1-2 days)
Secure Payment
Cash on delivery
Cagrilintide
Long-Acting Amylin Receptor Agonist | Weight Loss & Diabetes
In short
Modified amylin analog studied in clinical models of metabolic regulation and body weight control.
Best sellers
Related resources
Ready-to-use starter kit
Cagrilintide is a synthetic peptide that functions as a long-acting analogue of the naturally occurring hormone amylin. At the molecular level, it acts as a dual agonist by binding to both amylin and calcitonin receptors to modulate satiety signaling pathways. Scientists are currently testing it in laboratory and clinical studies, often combined with semaglutide, to evaluate its effects on metabolic regulation. This specific product is strictly for scientific research and is not an approved medication for human use.
Research reagent for laboratory use only. Not a medicine. For medical questions, consult a physician.
Scientific review
Written by
Калина Тодорова
Magister Pharmaciae, MSc Pharmacy
Reviewed by
Борис Маринов
MSc Biochemistry & Molecular Biology
Reviewed on
Cagrilintide (AM833) is a novel long-acting lipidated amylin analog that acts as a dual amylin and calcitonin receptor agonist. Developed for weight management and type 2 diabetes treatment, it shows superior weight loss potential when combined with semaglutide (CagriSema), with recent Phase 3 trials demonstrating up to 22.7% weight reduction.
Long-acting amylin analog (7-day half-life) CagriSema (cagrilintide + semaglutide) - 17.1% weight loss (Lancet 2021) Complementary to GLP-1 - additive effect Anorectic neurons in area postrema
Subcutaneous injection provides optimal bioavailability of lipidated amylin analog, targeting dual amylin and calcitonin receptors for satiety and metabolic effects
Phase 3 trials demonstrate 22.7% weight loss with CagriSema combination, outperforming existing therapies
15.7% weight loss in diabetic patients with concurrent glycemic improvements
Long-acting formulation supports sustained weight loss throughout treatment period
Dosing
The typical regimens you'll see in the published research - for reference when planning in vitro or in vivo experiments. Not medical advice.
Disclaimer
These are regimens discussed in the research literature, not medical advice. Consult a healthcare provider before use.
Timing
Same day weekly, preferably evening, with or without food
[Calculator]
Change water and dose · results update in real time
from product
Visual indicator
Pull to mark 10
10marks
Standard insulin syringe 1 ml (100 marks)
Concentration
2.50mg/ml
Dose volume
0.100ml
U-100 units
10units
Doses per vial
20doses
Recommended needle
29G–30G / 1 ml insulin
Small volume — draw slowly; 30G works for finer precision
Cycle planner: vials for 12 weeks, cost, schedule
Opens full calculator
Results are reference values - for in vitro work. Verify against the published literature for the specific peptide.
[Step by step]
6 steps from a sealed vial to the injection. Plain language.
Peptide vial (5 mg), bacteriostatic water vial, 1 larger syringe (3-5 ml) for drawing water and 1 insulin (1 ml) for doses. Alcohol swabs for sanitizing the caps.
Wash your hands before starting.
Wipe the rubber cap of the water vial with an alcohol swab. Insert the needle, invert the vial and draw exactly 2 ml. Get the exact volume from the calculator.
Larger syringe = smaller error in volume.
Wipe the peptide vial cap. Tilt the vial 45° and release the water SLOWLY down the inner wall. Peptides are fragile — a direct stream onto the powder denatures them.
SLOWLY · DOWN THE WALL · NOT ONTO THE POWDER.
Hold the vial between both palms and swirl slowly. DO NOT shake or flip sharply — peptides break down under mechanical stress.
DON'T SHAKE. Like tea — not like a cocktail.
The powder should fully dissolve. The solution is clear, no visible particles. If cloudy or with sediment — discard (wrong water or bad batch).
Clear = OK. Cloudy = discard.
With the insulin syringe draw the exact marks from the calculator. Swab the skin (abdomen 5 cm around the navel, thigh, or buttock), pinch a fold, insert at 45-90° and inject slowly.
Rotate sites every injection to avoid lipohypertrophy.
Schedule
Same day weekly, preferably evening, with or without food
Reconstitute slowly down side of vial, swirl gently (don't shake)
Verify solution is clear - any cloudiness or particles indicates fibril formation, discard immediately
Store refrigerated (2-8°C), inspect for clarity before each injection
Allow to reach room temperature 15-30 minutes before injection
Inject subcutaneously in abdomen, thigh, or upper arm, rotating sites weekly
Most common side effects are gastrointestinal (nausea, vomiting, diarrhea) during initial weeks
Anti-cagrilintide antibodies develop in 46-73% of patients but do not affect efficacy
No clinically significant QT prolongation observed in thorough QT studies
Only 57.3% of patients achieved maximum 2.4 mg dose in REDEFINE 1 trial
Formulation must be maintained at acidic pH (3.5-4.5) to prevent fibril formation and deamidation. Reconstituted solutions should be inspected for cloudiness or particles before each use
Compatibility
The pairings below come from research literature and established biohacker stacking patterns. Click a card for the full reasoning - when the partner is in our catalog you'll see a direct order link too.
This is a literature overview, not medical advice. Pairs not listed are not proven safe - they simply lack enough published data.
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
REDEFINE 1 Trial - Phase 3 Weight Loss (2025)
Humans | 2.4 mg weekly | 68 weeks | 22.7% weight loss vs 2.4% placebo
Landmark Phase 3 trial published in NEJM demonstrating superior weight loss with CagriSema combination in 3,417 adults with obesity, achieving primary endpoints with excellent safety profile
View the studyREDEFINE 2 Trial - Phase 3 Type 2 Diabetes (2025)
Humans | 2.4 mg weekly | 68 weeks | 15.7% weight loss, 73.5% achieved HbA1c ≤6.5%
Phase 3 trial in 1,206 adults with type 2 diabetes and obesity published in NEJM, demonstrating significant weight loss and glycemic improvements with CagriSema
View the studyThorough QT Study - Cardiac Safety (2024)
Humans | 4.5 mg single dose | 5 days | No clinically relevant QTc prolongation
Dedicated cardiac safety study confirming no significant QT interval prolongation at supratherapeutic doses, supporting cardiovascular safety profile
View the studyPhase 2 Type 2 Diabetes Combination Study (2023)
Humans | 2.4 mg weekly | 32 weeks | 15.6% weight loss, 2.2% HbA1c reduction with CagriSema
First study reporting efficacy of GLP-1/amylin combination in type 2 diabetes, showing superior weight loss and glycemic control versus individual components
View the studyPhase 2 Dose-Finding Monotherapy Trial (2021)
Humans | 0.3-4.5 mg weekly | 26 weeks | Up to 10.8% weight loss dose-dependent
Multi-center dose-finding trial in 706 participants demonstrating dose-dependent weight loss and establishing optimal 2.4 mg weekly dosing
View the studyPhase 1b Safety and Pharmacokinetics Study (2021)
Humans | 0.16-4.5 mg weekly | 20 weeks | Safety profile established
First-in-human combination study with semaglutide demonstrating acceptable safety profile and pharmacokinetic parameters for CagriSema development
View the study
for longevity
for sexual health
No reviews yet. Be the first.
Share your experience with this peptide. We publish after a short moderation.
